[go: up one dir, main page]

AR076195A1 - Anticuerpos biespecificos anti-erbb-1/anti-c-met - Google Patents

Anticuerpos biespecificos anti-erbb-1/anti-c-met

Info

Publication number
AR076195A1
AR076195A1 ARP100101124A ARP100101124A AR076195A1 AR 076195 A1 AR076195 A1 AR 076195A1 AR P100101124 A ARP100101124 A AR P100101124A AR P100101124 A ARP100101124 A AR P100101124A AR 076195 A1 AR076195 A1 AR 076195A1
Authority
AR
Argentina
Prior art keywords
seq
region
antigen binding
binding site
specifically binds
Prior art date
Application number
ARP100101124A
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of AR076195A1 publication Critical patent/AR076195A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Posee un ácido nucleico que codifica el anticuerpo biespecífico, una composicion farmacéutica que contiene el anticuerpo biespecífico, uso del anticuerpo biespecífico para la fabricacion de un medicamento destinado al tratamiento del cáncer. Reivindicacion 1: Un anticuerpo biespecífico que se une específicamente a la ErbB-1 humana y a la c-Met humana, que contiene un primer sitio de fijacion al antígeno que se une específicamente a la ErbB-1 humana y un segundo sitio de fijacion al antígeno que se une específicamente a la c-Met humana. Reivindicacion 4: Un anticuerpo biespecífico que se une específicamente a la ErbB-1 humana y a la c-Met humana que contiene un primer sitio de fijacion al antígeno que se une específicamente a la ErbB-1 humana y un segundo sitio de fijacion al antígeno que se une específicamente a la c-Met humana, caracterizado porque i) dicho primer sitio de fijacion al antígeno contiene en el dominio variable de cadena larga una region CDR3H de SEQ ID Ns:17, una region CDR2H de SEQ ID Ns:18 y una region CDR1H de SEQ ID Ns:19, y en el dominio variable de cadena corta una region CDR3L de SEQ ID Ns:20, una region CDR2L de SEQ ID Ns:21 y una region CDR1L de SEQ ID Ns: 58 o una region CDR1L de SEQ ID Ns:22; y dicho segundo sitio de fijacion al antígeno contiene en el dominio variable de cadena larga una region CDR3H de SEQ ID Ns:30, una region CDR2H de SEQ ID Ns:31, y una region CDR1H de SEQ ID Ns:32, y en el dominio variable de cadena corta una region CDR3L de SEQ ID Ns:33, una region CDR2L de SEQ ID Ns:34 y una region CDR1L de SEQ ID Ns:35; ii) dicho primer sitio de fijacion al antígeno contiene en el dominio variable de cadena larga una region CDR3H de SEQ ID Ns:23, una region CDR2H de SEQ ID Ns:24 y una region CDR1H de SEQ ID Ns:25, y en el dominio variable de cadena corta una region CDR3L de SEQ ID Ns:26, una region CDR2L de SEQ ID Ns:27 y una region CDR1L de SEQ ID Ns:28 o una region CDR1L de SEQ ID Ns:29; y dicho segundo sitio de fijacion al antígeno contiene en el dominio variable de cadena larga una region CDR3H de SEQ ID Ns: 30, una region CDR2H de SEQ ID Ns:31 y una region CDR1H de SEQ ID Ns:32, y en el dominio variable de cadena corta una region CDR3L de SEQ ID Ns:33, una region CDR2L de SEQ ID Ns: 34 y una region CDR1L de SEQ ID Ns: 35.
ARP100101124A 2009-04-07 2010-04-05 Anticuerpos biespecificos anti-erbb-1/anti-c-met AR076195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09005109 2009-04-07

Publications (1)

Publication Number Publication Date
AR076195A1 true AR076195A1 (es) 2011-05-26

Family

ID=40942332

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100101124A AR076195A1 (es) 2009-04-07 2010-04-05 Anticuerpos biespecificos anti-erbb-1/anti-c-met
ARP100101123A AR076194A1 (es) 2009-04-07 2010-04-05 Anticuerpos biespecificos anti-erbb-2/anti-c-met

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100101123A AR076194A1 (es) 2009-04-07 2010-04-05 Anticuerpos biespecificos anti-erbb-2/anti-c-met

Country Status (14)

Country Link
US (4) US20100254988A1 (es)
EP (2) EP2417160A1 (es)
JP (2) JP5612663B2 (es)
KR (2) KR20110126748A (es)
CN (2) CN102361883A (es)
AR (2) AR076195A1 (es)
AU (2) AU2010233993A1 (es)
BR (2) BRPI1014449A2 (es)
CA (2) CA2757669A1 (es)
IL (2) IL214847A0 (es)
MX (2) MX2011010158A (es)
SG (2) SG175078A1 (es)
TW (2) TW201039849A (es)
WO (2) WO2010115553A1 (es)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
CN103154255B (zh) 2010-08-02 2016-04-06 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
AU2011296085A1 (en) 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
US9562109B2 (en) * 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
KR101572338B1 (ko) * 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
CN103429619B (zh) * 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
NZ615738A (en) * 2011-04-04 2015-11-27 Nestec Sa Methods for predicting and improving the survival of gastric cancer patients
KR101723273B1 (ko) * 2011-08-23 2017-04-04 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
WO2013026833A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
DK2748202T3 (en) * 2011-08-23 2018-09-17 Roche Glycart Ag BISPECIFIC ANTI-BINDING MOLECULES
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
US9062120B2 (en) * 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2886422C (en) 2012-10-03 2022-12-13 Jason Baardsnes Methods of quantitating heavy and light chain polypeptide pairs
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
AU2013340799B2 (en) * 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
SG11201503938VA (en) * 2012-11-21 2015-06-29 Janssen Biotech Inc BISPECIFIC EGFR/c-Met ANTIBODIES
KR102411491B1 (ko) 2012-11-28 2022-06-22 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
BR112015017800A2 (pt) * 2013-02-26 2017-11-21 Roche Glycart Ag moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
KR102067613B1 (ko) * 2013-03-28 2020-01-20 삼성전자주식회사 항 c-Met 항체 및 항 her2 항체를 포함하는 병용 투여용 조성물
KR102049991B1 (ko) * 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102074421B1 (ko) * 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
KR102190220B1 (ko) * 2013-05-29 2020-12-14 삼성전자주식회사 타겟 특이적 세포막 단백질 제거용 조성물
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
US9879081B2 (en) * 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
KR102236367B1 (ko) * 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
CA2926262C (en) 2013-10-14 2025-06-17 Janssen Biotech, Inc. CYSTEINE MODIFIED TYPE III FIBRONECTIN DOMAIN BINDING MOLECULES (FN3)
EA039356B1 (ru) * 2013-10-18 2022-01-18 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
JP2017504566A (ja) * 2013-11-21 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗アルファ−シヌクレイン抗体及び使用方法
CN105980409B (zh) 2013-11-27 2023-07-18 酵活生物制药有限公司 靶向her2的双特异性抗原结合构建体
KR102178323B1 (ko) 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
JP6618912B2 (ja) 2013-12-20 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改良された、組換えポリペプチド作製方法
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
KR102194142B1 (ko) * 2014-01-20 2020-12-23 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
CN106062193B (zh) * 2014-02-28 2020-08-25 安斯泰来制药株式会社 与人tlr2及人tlr4结合的双特异性抗体
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN106164094B (zh) * 2014-03-21 2021-05-14 X博迪公司 双特异性抗原结合多肽
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
RS59907B1 (sr) 2014-03-28 2020-03-31 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
EP3137500A1 (en) 2014-04-30 2017-03-08 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Humanized antibodies against cd269 (bcma)
US9975960B2 (en) * 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
KR102401595B1 (ko) * 2014-05-09 2022-05-24 삼성전자주식회사 항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
WO2015182796A1 (en) * 2014-05-26 2015-12-03 Samsung Electronics Co., Ltd. Composition for combination therapy comprising anti-her2 antibody and anti-c-met antibody
RU2729467C2 (ru) 2014-05-28 2020-08-06 Займворкс Инк. Модифицированные антигенсвязывающие полипептидные конструкции и их применение
KR102259232B1 (ko) * 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
CN105888672B (zh) * 2014-09-02 2018-07-27 北京中煤矿山工程有限公司 一种斜冻结孔用外夹式下冻结管装置
CA2960569A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-Laroche Ag Fc-region variants with modified fcrn- and protein a-binding properties
WO2016079076A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules agiant folr1 and cd3
PL4141032T3 (pl) 2014-11-20 2024-09-16 F. Hoffmann-La Roche Ag Terapia skojarzona składająca się z dwuswoistych cząsteczek wiążących antygen aktywujących limfocyty T oraz antagonistów wiązania osi PD-1
HUE049650T2 (hu) 2014-11-20 2020-11-30 Hoffmann La Roche Közös könnyûláncok és alkalmazási eljárások
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
BR112018000835A2 (pt) * 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
DK3359576T3 (da) 2015-10-08 2025-01-27 Zymeworks Bc Inc Antigenbindende polypeptidkonstrukter omfattende lette kappa- og lambda-kæder og anvendelser deraf
CA3003759A1 (en) * 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
LT3468586T (lt) 2016-06-14 2024-12-10 Xencor, Inc. Bispecifiniai antikūnai prieš imuninės sistemos kontrolės taškų inhibitorius
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
NZ793452A (en) 2016-10-14 2025-09-26 Xencor Inc IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554562A4 (en) 2016-12-14 2020-11-04 Janssen Biotech, Inc. DOMAINS OF TYPE III FIBRONECTIN BINDING TO CD8A
US11820828B2 (en) 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR102078292B1 (ko) 2017-05-30 2020-02-19 주식회사 종근당 신규한 항 c-Met 항체 및 이의 용도
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111655718B (zh) 2017-12-19 2025-07-22 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
JP7657591B2 (ja) 2017-12-22 2025-04-07 アルジェニクス ビーブイ 二重特異性抗原結合コンストラクト
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
EP3768705A1 (en) * 2018-03-22 2021-01-27 Universität Stuttgart Multivalent binding molecules
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP7724061B2 (ja) 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
CN114173875B (zh) 2019-03-01 2025-04-15 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
KR102239781B1 (ko) 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
MA55705A (fr) * 2019-04-17 2022-02-23 Novo Nordisk As Anticorps bispécifiques
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
BR112023021325A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Domínios de fibronectina tipo iii de ligação a cd71
AU2022258584A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US20250230248A1 (en) 2021-10-18 2025-07-17 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
CN118742325A (zh) 2022-01-28 2024-10-01 上海岸阔医药科技有限公司 预防或治疗与抗肿瘤剂相关的疾病或病症的方法
JP2025505812A (ja) 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド 化合物及びその用途
JP2025537484A (ja) 2022-10-21 2025-11-18 ダイアゴナル・セラピューティクス・インコーポレイテッド Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
EP4624493A1 (en) * 2022-11-24 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr
CN121057752A (zh) 2023-04-07 2025-12-02 达科纳治疗有限公司 铰链经修饰的双特异性抗体
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025011470A1 (en) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Egfr/c-met bispecific binding protein and use thereof
WO2025011471A1 (en) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Egfr/c-met bispecific binding protein and use thereof
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
WO2025090519A1 (en) 2023-10-23 2025-05-01 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
CN120000805A (zh) * 2023-11-15 2025-05-16 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1991006305A1 (en) 1989-11-07 1991-05-16 Bristol-Myers Squibb Company Oligomeric immunoglobulins
EP0547137A4 (en) 1990-08-31 1993-12-08 Bristol-Myers Squibb Company Homoconjugated immunoglobulins
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2297692A1 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CA2690395C (en) * 1998-06-22 2013-11-05 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
WO2004072117A2 (en) 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
WO2005004809A2 (en) 2003-07-01 2005-01-20 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005011735A1 (en) 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
US20050227324A1 (en) 2003-12-19 2005-10-13 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CN1997382A (zh) * 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA95068C2 (uk) 2005-02-07 2011-07-11 Глікарт Біотехнолоджі Аг Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
RU2404193C2 (ru) * 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
KR101379568B1 (ko) 2005-08-26 2014-04-08 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
JP5536445B2 (ja) 2006-03-30 2014-07-02 ノバルティス アーゲー ｃ−Ｍｅｔの抗体の組成物およびその使用方法
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CA2670315A1 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2008282218A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
CN102014913A (zh) 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
US20090226455A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用

Also Published As

Publication number Publication date
JP2012522525A (ja) 2012-09-27
IL214847A0 (en) 2011-11-30
AU2010233995A1 (en) 2011-09-08
EP2417164A1 (en) 2012-02-15
BRPI1014474A2 (pt) 2017-06-27
CN102361883A (zh) 2012-02-22
AR076194A1 (es) 2011-05-26
MX2011010169A (es) 2011-10-11
SG175078A1 (en) 2011-11-28
IL214885A0 (en) 2011-11-30
JP5612663B2 (ja) 2014-10-22
TW201039849A (en) 2010-11-16
JP2012522523A (ja) 2012-09-27
CA2757669A1 (en) 2010-10-14
BRPI1014449A2 (pt) 2017-06-27
US20130273054A1 (en) 2013-10-17
TW201039848A (en) 2010-11-16
EP2417160A1 (en) 2012-02-15
SG175080A1 (en) 2011-11-28
US20100254988A1 (en) 2010-10-07
US20130156772A1 (en) 2013-06-20
WO2010115551A1 (en) 2010-10-14
CA2757426A1 (en) 2010-10-14
CN102361884A (zh) 2012-02-22
KR20110124368A (ko) 2011-11-16
AU2010233993A1 (en) 2011-09-08
JP5497887B2 (ja) 2014-05-21
MX2011010158A (es) 2011-10-17
KR20110126748A (ko) 2011-11-23
WO2010115553A1 (en) 2010-10-14
US20100254989A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
AR076195A1 (es) Anticuerpos biespecificos anti-erbb-1/anti-c-met
PE20120550A1 (es) ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
CL2012003283A1 (es) Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.
AR118047A2 (es) Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
UY32341A (es) Proteínas de unión antígeno novedosas
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
AR073775A1 (es) Anticuerpos biespecificos anti-vegf/anti- ang -2
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
PE20142422A1 (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
PE20121616A1 (es) Anticuerpos anti-her3
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)

Legal Events

Date Code Title Description
FB Suspension of granting procedure